SMAIO

SMAIO Equity Ratio

The Equity Ratio of SMAIO (ALSMA.PA) as of Oct 20, 2026 is 42.59 %. In the previous year, Equity Ratio was 58.05 % — a change of -26.63% (lower).

Equity Ratio

42.59 %

YoY

-26.63%

Last updated:

Equity Ratio of SMAIO is 2025 42.59 % . Equity Ratio of SMAIO was 2024 58.05 % . It decreases by -26.63% lower compared to the previous year.

The SMAIO Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-18.60 EUR
Jan 1, 2019
46.56 EUR
Jan 1, 2020
-6.78 EUR
Jan 1, 2021
-7.50 EUR
Jan 1, 2022
81.56 EUR
Jan 1, 2023
71.27 EUR
Jan 1, 2024
58.05 EUR
Jan 1, 2025
42.59 EUR
The SMAIO Equity Ratio history
YEAREquity RatioYoY
42.59 %-26.63%
58.05 %-18.55%
71.27 %-12.62%
81.56 %-1,187.49%
-7.50 %+10.57%
-6.78 %-114.57%
46.56 %-350.31%
-18.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SMAIO Stock analysis

What does SMAIO do? S.M.A.I.O SA generates revenue through its comprehensive suite of medical devices and software solutions designed for spinal surgery. The company offers the Kheiron Spinal Fixation System, which includes implants for immobilizing and stabilizing spinal segments during fusion procedures. Its software solutions, such as i-plan, i-perform, i-check, and i-learn, provide spine surgeons with surgical planning, procedure control, outcome data analysis, and educational resources. The firm targets spine surgeons and specialists in spinal pathologies who require advanced tools for vertebral fusion procedures. The company's revenue streams include the sale of implantable devices like the Kheiron Spinal Fixation System and licensing of its software platforms, including Keops and Balance Analyzer 3D. These products are marketed to spine surgery specialists who use the clinical data and imaging tools to enhance surgical outcomes. The firm's offerings integrate software, devices, and services to address spinal pathologies requiring surgical intervention. S.M.A.I.O SA's business model focuses on delivering end-to-end solutions for spine surgery, combining hardware, software, and educational services. The Kheiron Spinal Fixation System serves as a core product for spinal immobilization, while Keops and Balance Analyzer 3D cater to surgical planning and patient data management. These products are sold directly to spine surgeons and medical specialists who rely on the company's integrated approach to improve surgical precision and patient outcomes. SMAIO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SMAIO stock

Equity Ratio of SMAIO is 42.59 % in 2025.

Equity Ratio of SMAIO changed from 58.05 % to 42.59 %, representing a -26.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio SMAIO since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's SMAIO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SMAIO

All Key Metrics — SMAIO